Cell and gene therapies (CGTs) are a growing option in the rare disease treatment landscape. Some rare conditions can be identified with claims data, but others are acute and arise without warning. Predicting exposure to CGTs is critical to appropriately capturing the risk associated with covering these innovative and expensive new treatment options. This session will focus on two major uncertainties in the CGT space: (1) forecasting CGT treatment eligibility within a covered population using clinical research and claims data analysis and (2) understanding the factors that impact the demand and timing of the first claims.
Learning objectives:
Attendees will be able to identify complexities in identifying cases and forecasting CGTs using claims data and other research.
Attendees will be able to identify factors that can delay or impact demand and uptake of CGTs, and resources that can help inform this information.